Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II/III study of SM-88 in patients with metastatic pancreatic cancer
Vincent Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Valeria Merz et al.
FRONTIERS IN ONCOLOGY (2021)
P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
A. Schram et al.
Journal of Thoracic Oncology (2021)
Sotorasib: First Approval
Hannah A. Blair
DRUGS (2021)
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
Raffaella Casolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial
Laetitia Dahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
Nai-Jung Chiang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Christopher T. Su et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
Andrew E. Greenstein et al.
Oncotarget (2021)
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Bruno L. Cadilha et al.
SCIENCE ADVANCES (2021)
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Stefanie Lesch et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
Archana Thakur et al.
ONCOIMMUNOLOGY (2021)
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Zhaozhen Wu et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2021)
A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer
Jeanetta Stega et al.
INVESTIGATIONAL NEW DRUGS (2020)
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Steven C. Katz et al.
CANCER GENE THERAPY (2020)
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Luca Richeldi et al.
LANCET RESPIRATORY MEDICINE (2020)
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Max M. Wattenberg et al.
BRITISH JOURNAL OF CANCER (2020)
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial
Pascal Hammel et al.
EUROPEAN JOURNAL OF CANCER (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Sara K. Daniel et al.
SEMINARS IN CANCER BIOLOGY (2020)
The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction
Huiying Huang et al.
CANCER LETTERS (2020)
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
Yang Liu et al.
CYTOTHERAPY (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Hemant M. Kocher et al.
NATURE COMMUNICATIONS (2020)
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
Steven C. Katz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer
Vincent Picozzi et al.
ESMO OPEN (2020)
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion
Patrick W. Burke et al.
ESMO OPEN (2020)
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas
Caron A. Jacobson et al.
BLOOD ADVANCES (2020)
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
Lawrence G. Lum et al.
ONCOIMMUNOLOGY (2020)
Why is pancreatic cancer so deadly? The pathologist's view
Ralph H. Hruban et al.
JOURNAL OF PATHOLOGY (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Zebin Wang et al.
SCIENTIFIC REPORTS (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
Metabolic regulation of cell growth and proliferation
Jiajun Zhu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters
Yong Gu Lee et al.
NATURE COMMUNICATIONS (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas
Philip A. Philip et al.
FUTURE ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Linchun Jin et al.
NATURE COMMUNICATIONS (2019)
Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors
Yong Gu Lee et al.
CANCER RESEARCH (2019)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Maura C. O'Leary et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj et al.
CLINICAL CANCER RESEARCH (2019)
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Vinod P. Balachandran et al.
GASTROENTEROLOGY (2019)
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Herbert Hurwitz et al.
ONCOLOGIST (2019)
Characterization of zolbetuximab in pancreatic cancer models
Oezlem Tuereci et al.
ONCOIMMUNOLOGY (2019)
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
Mylinh T. Duong et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer
Shigeaki Sunada et al.
CANCER SCIENCE (2018)
Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells
Santosh Kumar Singh et al.
SCIENTIFIC REPORTS (2018)
Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Aung Naing et al.
CANCER RESEARCH (2018)
A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer
Dung Le et al.
CANCER RESEARCH (2018)
Pancreatic cancer: challenges and opportunities
Huiyun Zhu et al.
BMC MEDICINE (2018)
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar et al.
LANCET ONCOLOGY (2017)
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Somala Mohammed et al.
MOLECULAR THERAPY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
Hao Zhang et al.
International Journal of Biological Sciences (2016)
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal et al.
BRITISH JOURNAL OF CANCER (2015)
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Clifford J. Whatcott et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma
Jean-Baptiste Bachet et al.
PANCREAS (2015)
Suppression of cancer relapse and metastasis by inhibiting cancer stemness
Youzhi Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Multiple regulation pathways and pivotal biological functions of STAT3 in cancer
Jie Yuan et al.
SCIENTIFIC REPORTS (2015)
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra et al.
CANCER RESEARCH (2014)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Daniel Abate-Daga et al.
HUMAN GENE THERAPY (2014)
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
Stefan Woell et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases
Lianyu Chen et al.
SCIENTIFIC REPORTS (2014)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
J. M. Loehr et al.
ANNALS OF ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 Summary and conclusions
D. M. Parkin et al.
BRITISH JOURNAL OF CANCER (2011)
Retinoic Acid-Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt-β-Catenin Signaling to Slow Tumor Progression
Fieke E. M. Froeling et al.
GASTROENTEROLOGY (2011)
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Zuzana Zachar et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies
Masao Kobayakawa et al.
ONCOTARGETS AND THERAPY (2011)
Engineered T cells for pancreatic cancer treatment
Usha L. Katari et al.
HPB (2011)
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
S. Singh et al.
BRITISH JOURNAL OF CANCER (2010)
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Yangbing Zhao et al.
CANCER RESEARCH (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Interleukin-8 Pathway in Cancer
David J. J. Waugh et al.
CLINICAL CANCER RESEARCH (2008)
Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
U Reusch et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
